Benzinga - by Lisa Levin, Benzinga Editor.
U.S. stocks traded slightly higher, with the Nasdaq Composite gaining around 10 points on Monday. Here are some big stocks recording losses in today’s session.
Li-Cycle Holdings Corp. (NYSE: LICY) shares dipped 41% to $1.34 after the company announced plans to halt construction work on its Rochester Hub project, pending completion of a comprehensive review of the go-forward strategy for the project.
Revolution Medicines, Inc. (NASDAQ: RVMD) fell 38% to $17.31 after the company announced it presented clinical activity and safety data from its Phase 1/1b trial of RMC-6236.
Ambrx Biopharma Inc. (NASDAQ: AMAM) declined 22% to $6.58. Ambrx announced ARX517, a PSMA-targeted ADC, demonstrates 52% PSA50 (≥50% Reduction) and a highly differentiated safety and PK profile in patients with mCRPC, who progressed on multiple FDA-approved treatments.
FMC Corporation (NYSE: FMC) fell 13.7% to $57.76 after the company updated its third-quarter and FY23 outlook.
VinFast Auto Ltd. (NASDAQ: VFS) fell 11.4% to $4.76. The company recently entered into a standby equity agreement with YA LL PN for an aggregate subscription amount of up to $1 billion.
NewAmsterdam Pharma Company N.V. (NASDAQ: NAMS) declined 11.4% to $6.25. NewAmsterdam Pharma named Ian Somaiya as Chief Financial Officer.
FingerMotion, Inc. (NASDAQ: FNGR) fell 8.8% to $5.76.
YPF Sociedad Anónima (NYSE: YPF) fell 8.5% to $11.24.
Okta, Inc. (NASDAQ: OKTA) declined 7.6% to $69.85 on continued downward momentum after a threat actor breached its support system and viewed certain customer files. Also, Keybanc maintained an Overweight rating on the stock but lowered its price target from $106 to $95.
World Acceptance Corporation (NASDAQ: WRLD) fell 6.8% to $103.71 after BMO Capital maintained an Underperform rating on the stock and lowered its price target from $58 to $56.
Perfect Corp. (NYSE: PERF) fell 6.8% to $2.61.
Formula Systems (1985) Ltd. (NASDAQ: FORTY) declined 6% to $55.97.
Now Read This: Hexcel Likely To Report Higher Q3 Earnings; Here's A Look At Recent Price Target Changes By The Most Accurate Analysts
© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.